Organon & Co. (OGN)
NYSE: OGN · Real-Time Price · USD
8.44
-0.27 (-3.10%)
May 13, 2025, 4:00 PM - Market closed
Organon & Co. Revenue
Organon & Co. had revenue of $1.51B in the quarter ending March 31, 2025, a decrease of -6.72%. This brings the company's revenue in the last twelve months to $6.29B, down -0.84% year-over-year. In the year 2024, Organon & Co. had annual revenue of $6.40B with 2.24% growth.
Revenue (ttm)
$6.29B
Revenue Growth
-0.84%
P/S Ratio
0.35
Revenue / Employee
$629,400
Employees
10,000
Market Cap
2.19B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
OGN News
- 21 hours ago - Bronstein, Gewirtz & Grossman, LLC Encourages Organon & Co. (OGN) Stockholders to Inquire about Securities Investigation - Accesswire
- 1 day ago - Organon & Co: Cost Takeout Catalysts, Initiate Strong Buy - Seeking Alpha
- 1 day ago - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Organon & Co. (OGN) and Encourages Investors to Learn More About the Investigation - Accesswire
- 2 days ago - Bronstein, Gewirtz & Grossman, LLC Is Investigating Organon & Co. (OGN) And Encourages Stockholders to Connect - Accesswire
- 4 days ago - Organon & Co. (OGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - Accesswire
- 5 days ago - Organon: Management Slashes Dividend - This Feels Disastrous - Seeking Alpha
- 5 days ago - EU drugs regulator confirms suicidal thoughts as side effect of anti hair-loss drug - Reuters
- 5 days ago - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Organon & Co. (OGN) and Encourages Stockholders to Learn More About the Investigation - Accesswire